Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00525824 | 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe | PHASE3 | COMPLETED | 1,743 | — | — | Aug 1, 2007 | Sep 1, 2008 | May 13, 2011 | 9 | United States, Argentina +7 |
| NCT00653445 | Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg | PHASE3 | COMPLETED | - | — | — | Jun 1, 2004 | Jun 1, 2005 | Mar 26, 2009 | - | — |
Percent change in LDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Rosuvastatin 40mg/Ezetimibe 10mg combination therapy |
| 2 | EXPERIMENTAL | Rosuvastatin 40 mg |
| Name | Type | Description |
|---|---|---|
| Rosuvastatin (Crestor) | DRUG | 10mg and 20 mg |
| Ezetimibe | DRUG | 10 mg |
| Simvastatin | DRUG | 40mg and 80 mg |
| Rosuvastatin | DRUG | 40mg |
Inclusion Criteria: * Patients with with hypercholesterolaemia and CHD or a CHD risk equivalent, clinical evidence of atherosclerosis or a Framingham 10-year CHD risk score of \>20 * Patients will need to sign an informed consent before any visit procedures can be performed, including procedures fo...